Oral antithrombotic effects of acylhydrazone derivatives

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 3, 2013, Pages 287-295

  Frattani, Flávia Serra ^a   Coriolano, Eduardo Oliveira ^a   Lima, Lidia Moreira ^a   Barreiro, Eliezer Jesus ^a   Zingali, Russolina Benedeta ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Acylhydrazones; Antiplatelet drugs; PAR; Platelet; Pulmonary thromboembolism; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; FIBRINOGEN; HEPARIN; INDOMETACIN; NORADRENALIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARGON PLASMA COAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; IN VITRO STUDY; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; THROMBOCYTE AGGREGATION;

EID: 84875391920     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14886     Document Type: Article

References (33)

1. Dominick JA, Masafumi U, Shinya G: Basic Principles of Platelet Biology and Clinical Implications. Circ J, 2010; 74: 597-607
2. Michelson AD: Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov, 2010; 9: 154-169
3. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 1991; 64: 1057-1068
4. Coughlin SR, Vu TK-H, Hung DT, Wheaton VI: Characterization of the cloned platelet thrombin receptor: issues and opportunities. J Clin Invest, 1992; 89: 351-355
5. Coughlin SR, Faruqi TR, Weiss EJ, Shapiro MJ, Huang W: Structure-Function Analysis of Protease-activated Receptor 4 Tethered Ligand Peptides. J Biol Chem, 2000; 275: 19728-19734
6. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Tam C, Coughlin SR: A dual thrombin receptor system for platelet activation. Nature, 1998; 394: 690-694
7. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR: PAR3 is a cofactor for PAR4 activation by thrombin. Nature, 2000; 404: 609-613
8. Bah A, Chen Z, Bush-Pelc LA, Mathews FS, Di Cera E: Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci USA, 2007; 104: 11603-11608
9. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR: Protection against thrombosis in mice lacking PAR3. Blood, 2002; 100: 3240-3244
10. Gresele P, Agnelli G: Novel approaches to the treatment of thrombosis TRENDS in Pharm Scienc, 2002; 23: 25-32
11. Morrell CN, Sun N, Ikeda M, Beique JC, Swaim AN, Mason E, Martin T, Thompson L, Gozen O, Ampagoomian D, Sprengel R, Rothstein J, Faraday N, Huganir R, Lowenstein CJ: Glutamate mediates platelet activation through the AMPA receptor. J Exp Med, 2008; 20: 575-584
12. Mackman N: Triggers, targets and treatments for thrombosis. Nature, 2008; 451: 914-918
13. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P: Therapeutic potential of protease-activated receptor-1 antagonists. Exper Opin Investig Drugs, 2003; 12: 209-221
14. Lima LM, Frattani FS, Dos Santos JL, Castro HC, Fraga CA, Zingali RB, Barreiro EJ: Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates. Eur J Med Chem, 2008; 43: 348-356
15. Born GV, Cross MJ: The Aggregation of Blood Platelets. J Physiol, 1963; 168: 178-195
16. Gresele P, Momi S, Berrettini M: Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest, 1998; 101: 667-676
17. Mendes-Silva W, Assafim M, Ruta B, Monteiro RQ, Guimarães JA, Zingali RB: Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor Thromb Res, 2003; 112: 93-98
18. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, Ruggeri ZM: Unique pathway of thrombininduced platelet aggregation mediated by glycoprotein-Ib. J Biol Chem, 2001; 276: 21173-21183
19. Reis AL, Ormelli CB, Miranda AL, Fraga CA, Barreiro EJ: Studies on antiplatelet agents from natural safrole II. Synthesis and pharmacological properties of novel functionalized oxime O-benzylether derivatives. Pharm Acta Helv, 1999; 74: 19-28
20. Nilsson T, Sjöling-Ericksson A, Deinum J: The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J Enzyme Inhib, 1998; 13: 11-29
21. Ho SJ, Brighton TA: Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag, 2006; 2: 49-58
22. Leblond L, Grouix B, Boudreau C, Yang Q, Siddiqui MA, Winocour PD: In Vitro and in vivo Properties of Bicyclic Lactam Inhibitors: A Novel Class of Low Molecular Weight Peptidomimetic Thrombin Inhibitors. Thromb Res, 2000; 100: 195-209
23. Ossovskaya VS, Bunnett NW: Protease-Activated Receptors: Contribution to Physiology and Disease. Am Physio Soc, 2004; 84: 579-621
24. Soslau G, Ando A, Floyd L, Hong T, Mathew L, Yen Y: Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation. J Thromb Thrombolysis, 2008; 25: 198-203
25. Mao Y, Jin J, Kunapuli SP: Characterization of a new peptide agonist of the protease-activated receptor-1. Biochem. Pharmacol, 2008; 75: 438-447
26. Wu CC, Huang SW, Hwang TL, Kuo SC, Lee FY, Teng CM: YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol, 2000; 130: 1289-1296
27. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, Teng CM: Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost, 2002; 87: 1026-1033
28. Prandoni P, Bernardi E, Bagatella P, Piccioli A, Marchiori A: The optimal treatment of venous thrombosis: current status and future perspectives. Clin Lab, 2001; 47: 151-154
29. Prandoni P, Simioni P, Pagnan A: Therapeutic indications for acute venous thromboembolism. Current status and future perspectives. Minerva Cardioangiol, 2003; 51: 361-371
30. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost, 2010; 103: 572-585
31. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N: Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost, 2007; 98: 333-338
32. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, Straub A: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost, 2005; 3: 514-521
33. Wong PC, Crain EJ, Watson CA, Xin B: Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared to the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost, 2009; 7: 1313-1320